Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

Related Keywords

Minnesota ,United States ,Texas ,American ,Carol Aghajanian ,Howards Hochster ,Robink Kelley ,Khalid Matin ,Emily Henderson ,Puneet Cheema ,Jaykumar Thumar ,Rachna Shroff ,Bristol Myers Squibb ,E Gabriela Chiorean ,Renukav Iyer ,Katherine Guthrie ,Anujk Patel ,Anthonyb El Khoueiry ,Sloan Kettering ,Philipa Philip ,Aaronj Scott ,Milind Javle ,Lauraw Goff ,Amit Mahipal ,National Cancer Institute ,Celgene Corporation ,Siteman Cancer Center ,Data Management Center ,Fred Hutchinson Cancer Center ,Washington University ,Cancer Research Network ,University Of Washington School Medicine ,Roswell Park Cancer Institute ,Vanderbilt University ,Rutgers Cancer Institute ,Massey Cancer Center ,Yale University ,National Clinical Trials Network ,University Of Texas Md Anderson Cancer Center ,National Institutes Of Health ,Ingram Cancer Center ,University Of Arizona Cancer Center ,Dana Farber Harvard Cancer Center ,Norris Comprehensive Cancer Center ,Case Western Reserve University ,Northwestern University ,University Of Arizona ,Research Network ,Cancers Symposium ,American Society ,Clinical Oncology ,Uarizona Cancer ,Discovery Industry Focus ,National Institutes ,Clinical Trials Network ,Henry Ford Cancer Institute ,Wayne State University ,Mayo Clinic ,Cancer Center ,Aparna Kalyan ,Memorial Sloan Kettering ,Benjamin Tan ,Metro Minnesota Community Oncology Research ,Saint John ,Harvard Cancer Center ,Washington School ,Rutgers Cancer ,Cancer ,Paclitaxel ,Adenocarcinoma ,Cholangiocarcinoma ,Cisplatin ,Gemcitabine ,Medicine ,Ncology ,Research ,